33504551 33504551 Deegen P, Thomas O, Nolan-Stevaux O et al (2021) The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.